Target intelligence / Profile preview

Obscurin-like cytoskeletal adaptor 1 (OBSL1)

Target
OBSL1
Molecular classification
Cytoskeletal adaptor protein, Member of the Unc-89/obscurin family
01

Overview

Obscurin-like cytoskeletal adaptor 1 (OBSL1) is a large, multi-domain cytoskeletal adaptor protein that plays a critical role in linking the internal cytoskeleton of cells to the cell membrane and organizing cellular architecture[1][5]. It is broadly expressed and localizes to structures such as intercalated discs, Z lines, and perinuclear regions, especially in muscle cells, where it helps stabilize contacts among cytoskeletal networks and membrane-bound complexes[1]. OBSL1 contains multiple immunoglobulin-like domains and a central fibronectin type 3 domain, enabling extensive protein-protein interactions that support cellular and tissue structural integrity[1][5]. Functionally, OBSL1 is a core component of the 3M complex, regulating microtubule dynamics, genome maintenance, and the Cul7-based E3 ubiquitin ligase pathway involved in protein turnover and Golgi organization[2][4]. Germline mutations in OBSL1 cause 3-M syndrome, a rare disorder of skeletal growth and development, highlighting its importance in growth hormone response pathways[4][5]. OBSL1 is not recognized as a therapeutic target, nor are there drugs or clinical biomarkers related to it at present.

Other names
OBSL1obscurin-like protein 1KIAA0657obscurin like 1
02

Biological functions

Cytoskeletal organization and linkageScaffolding of signaling complexesRegulation of the ubiquitin-proteasome system (via interaction with cullin-7/E3 ubiquitin ligase)Regulation of microtubule dynamicsMaintenance of genome integrityGolgi morphogenesis and dendrite patterning in the brain
03

Disease associations

3-M syndrome (growth retardation syndrome, type 2)Disrupted cytoskeletal or sarcomere integrity (predisposing to myopathies, but not directly linked as a major cancer/inflammatory target)
04

Safety considerations

Loss-of-function mutations are associated with severe disease (3-M syndrome), but no therapeutic interventions or safety concerns as a drug target are known

Beyond the preview

Go deeper on Obscurin-like cytoskeletal adaptor 1 (OBSL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Obscurin-like cytoskeletal adaptor 1 (OBSL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call